Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature
Light chain deposition disease (LCDD) is a clonal plasma cell disorder characterized by the deposition of nonamyloid monoclonal light chains in multiple organs. It can affect various systems throughout the body, mainly the kidneys. Symptoms may include renal insufficiency, proteinuria, hematuria, an...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1466323/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582003206127616 |
|---|---|
| author | Xueying Chen Jie Sun Pingyan Shen Zijin Chen Wen Zhang |
| author_facet | Xueying Chen Jie Sun Pingyan Shen Zijin Chen Wen Zhang |
| author_sort | Xueying Chen |
| collection | DOAJ |
| description | Light chain deposition disease (LCDD) is a clonal plasma cell disorder characterized by the deposition of nonamyloid monoclonal light chains in multiple organs. It can affect various systems throughout the body, mainly the kidneys. Symptoms may include renal insufficiency, proteinuria, hematuria, and others. Due to the lack of effective treatment, LCDD patients with kidney involvement often progress to chronic kidney failure, ultimately requiring renal replacement therapy. Daratumumab, an anti-CD38 monoclonal antibody, is primarily used for the treatment of relapsed and refractory multiple myeloma. Recent studies have shown that daratumumab also has an encouraging effect on light-chain amyloidosis. Here, we report the case of an LCDD (κ chain) patient with proteinuria, renal insufficiency, and anemia who was followed up for 3 years, during which he received daratumumab treatment. After the daratumumab treatment, the hematologic response continued progressing to a complete response without any adverse effects and continuous renal function improvement at a low serum free light chain (sFLC) level. This case shows that daratumumab is effective at treating LCDD. For LCDD patients with kidney involvement, frequent monitoring and active control of free light chain levels are necessary, as reaching the lowest sFLC of < 20 mg/L may help to improve kidney function. |
| format | Article |
| id | doaj-art-0777b449ddcf4091afcbb0b35e07964c |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-0777b449ddcf4091afcbb0b35e07964c2025-01-30T06:22:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.14663231466323Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literatureXueying Chen0Jie Sun1Pingyan Shen2Zijin Chen3Wen Zhang4Department of Nephrology, School of Medicine, Ruijin Hospital Shanghai Jiao Tong University, Wuxi, Jiangsu, ChinaDepartment of Nephrology, School of Medicine, Ruijin Hospital Shanghai Jiao Tong University, Wuxi, Jiangsu, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaLight chain deposition disease (LCDD) is a clonal plasma cell disorder characterized by the deposition of nonamyloid monoclonal light chains in multiple organs. It can affect various systems throughout the body, mainly the kidneys. Symptoms may include renal insufficiency, proteinuria, hematuria, and others. Due to the lack of effective treatment, LCDD patients with kidney involvement often progress to chronic kidney failure, ultimately requiring renal replacement therapy. Daratumumab, an anti-CD38 monoclonal antibody, is primarily used for the treatment of relapsed and refractory multiple myeloma. Recent studies have shown that daratumumab also has an encouraging effect on light-chain amyloidosis. Here, we report the case of an LCDD (κ chain) patient with proteinuria, renal insufficiency, and anemia who was followed up for 3 years, during which he received daratumumab treatment. After the daratumumab treatment, the hematologic response continued progressing to a complete response without any adverse effects and continuous renal function improvement at a low serum free light chain (sFLC) level. This case shows that daratumumab is effective at treating LCDD. For LCDD patients with kidney involvement, frequent monitoring and active control of free light chain levels are necessary, as reaching the lowest sFLC of < 20 mg/L may help to improve kidney function.https://www.frontiersin.org/articles/10.3389/fonc.2025.1466323/fulllight chain deposition diseasefree light chaindaratumumabrenal functionproteinuria |
| spellingShingle | Xueying Chen Jie Sun Pingyan Shen Zijin Chen Wen Zhang Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature Frontiers in Oncology light chain deposition disease free light chain daratumumab renal function proteinuria |
| title | Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature |
| title_full | Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature |
| title_fullStr | Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature |
| title_full_unstemmed | Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature |
| title_short | Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature |
| title_sort | daratumumab treatment for kidney involved light chain deposition disease prevents renal function progression a case report with 3 years of follow up and review of the literature |
| topic | light chain deposition disease free light chain daratumumab renal function proteinuria |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1466323/full |
| work_keys_str_mv | AT xueyingchen daratumumabtreatmentforkidneyinvolvedlightchaindepositiondiseasepreventsrenalfunctionprogressionacasereportwith3yearsoffollowupandreviewoftheliterature AT jiesun daratumumabtreatmentforkidneyinvolvedlightchaindepositiondiseasepreventsrenalfunctionprogressionacasereportwith3yearsoffollowupandreviewoftheliterature AT pingyanshen daratumumabtreatmentforkidneyinvolvedlightchaindepositiondiseasepreventsrenalfunctionprogressionacasereportwith3yearsoffollowupandreviewoftheliterature AT zijinchen daratumumabtreatmentforkidneyinvolvedlightchaindepositiondiseasepreventsrenalfunctionprogressionacasereportwith3yearsoffollowupandreviewoftheliterature AT wenzhang daratumumabtreatmentforkidneyinvolvedlightchaindepositiondiseasepreventsrenalfunctionprogressionacasereportwith3yearsoffollowupandreviewoftheliterature |